Evan Lippman insider trades: Teva Pharmaceutical Industries (TEVA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Evan reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | TEVA | ↓ Sell | 18,600 | $36.57 | $680K | Direct | Aug 19, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TEVA insiders
Open-market trades in the last 12 months
About Evan Lippman's insider trades
Evan Lippman is EVP, Business Development at Teva Pharmaceutical Industries (TEVA). Since Aug 17, 2026, Evan has reported no open-market purchases and 1 sale worth $680K on SEC Form 4. In the last 12 months: 1 sale ($680K).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TEVA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.